Stereochemistry | RACEMIC |
Molecular Formula | C15H23NO2 |
Molecular Weight | 249.3486 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C[C@H]1CCCC[C@]1(O)C2=CC(O)=CC=C2
InChI
InChIKey=UWJUQVWARXYRCG-HIFRSBDPSA-N
InChI=1S/C15H23NO2/c1-16(2)11-13-6-3-4-9-15(13,18)12-7-5-8-14(17)10-12/h5,7-8,10,13,17-18H,3-4,6,9,11H2,1-2H3/t13-,15+/m1/s1
Molecular Formula | C15H23NO2 |
Molecular Weight | 249.3486 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
O-Desmethyl tramadol (O-Desmethyltramadol, O-DSMT) is a metabolite of tramadol. O-Desmethyltramadol is an opioid analgesic and the main active metabolite of tramadol. (+)-O-Desmethyltramadol is the most important metabolite of tramadol produced in the liver after tramadol is consumed. This metabolite is considerably more potent as a μ-opioid agonist than the parent compound. O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in xenopus oocytes. O-desmethyl tramadol inhibits functions of M(1) receptors but has little effect on those of M(3) receptors. O-desmethyl tramadol has been widely used clinically and has analgesic activity.
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
Oral
Light: 15 – 30 mg
Common: 30 – 50 mg
Strong: 50 – 70+ mg
Route of Administration:
Oral
O-desmethyl tramadol (0.1-100 uM) inhibited acetylcholine (ACh)-induced currents in oocytes expressing the M(1) receptors (half-maximal inhibitory concentration [IC(50)] = 2 +/- 0.6 uM), whereas it did not suppress ACh-induced currents in oocytes expressing the M(3) receptor. O-desmethyl tramadol inhibited the specific binding of [(3)H]quinuclidinyl benzilate ([(3)H]QNB) to the oocytes expressed M(1) receptors (IC(50) = 10.1 +/- 0.1 uM), whereas it did not suppress the specific binding of [(3)H]QNB to the oocytes expressed M(3) receptors.